Dr. Florian Rader and Dr. C. Michael Gibson Discuss: Updated Cumulative Results Of Treatment With Mavacamten From The EXPLORER-LTE Cohort Of The MAVA-LTE Study In Patients With Obstructive Hypertrophic Cardiomyopathy April 3, 2022 Disclosures: TBA
Dr. Steven Nissen and Dr. C. Michael Gibson Discuss: APOLLO Trial: Magnitude And Duration Of Effects Of A Short-interfering RNA Targeting Lipoprotein(a): A Placebo-controlled Double-blind Dose-ranging Trial April 3, 2022 Disclosures: TBA
Dr. Gregory Lewis and Dr. C. Michael Gibson Discuss: METEORIC-HF: The Effect Of Omecamtiv Mecarbil On Exercise Tolerance In Patients With Chronic Heart Failure And Reduced Ejection Fraction April 3, 2022 Disclosures: TBA
Dr. Brian Bergmark and Dr. Yazan Daaboul Discuss: TRANSLATE-TIMI 70: Effect Of Vupanorsen On Non-high-density Lipoprotein Cholesterol Levels In Statin-treated Patients With Elevated Cholesterol April 3, 2022 Disclosures: TBA
Dr. Frederik Zimmermann and Dr. Yaz Daaboul Discuss: The FAME 3 Trial: Quality Of Life After Fractional Flow Reserve-guided Stenting Compared With Coronary Bypass Surgery April 2, 2022 Disclosures: TBA
Dr. PJ Devereaux and Dr. Serge Korjian Discuss: The Poise-3 Trial: Efficacy And Safety Of Tranexamic Acid In Patients Undergoing Noncardiac Surgery April 2, 2022 Disclosures: TBA
Dr. Justin Ezekowitz and Dr. C. Michael Gibson Discuss: SODIUM-HF: Study Of Dietary Intervention Under 100 Mmol In Heart Failure April 2, 2022 Disclosures: TBA
Dr. Milind Desai and Dr. C. Michael Gibson Discuss: VALOR-HCM: Mavacamten As An Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy April 2, 2022 Disclosures: TBA
Dr. Rafael Diaz and Dr. Serge Korjian Discuss: PREPARE-IT 2: Icosapent Ethyl Versus Placebo in Outpatients With Covid-19 November 15, 2021 Disclosures: TBD
Dr. John Spertus and Dr. Yazan Daaboul Discuss: CHIEF-HF: The Canagliflozin Impact on Health Status, Quality of Life and Functional Status in Heart Failure November 14, 2021 Disclosures: TBD
